Why Onglyza™?

Onglyza is a once-daily prescription medicine for adults with type 2 diabetes that enhances the body's natural ability to control blood sugar. Onglyza, along with diet and exercise, may help reduce after-meal blood sugar spikes. Onglyza may help lower your blood sugar between meals.

Most people taking Onglyza did not experience hypoglycemia (very low blood sugar); however, it may occur, particularly when taken with another diabetes medicine, such as a sulfonylurea. Symptoms of low blood sugar include shaking, sweating, rapid heartbeat, change in vision, hunger, headache and change in mood.

Here's how Onglyza may give you extra help to treat high blood sugar:

  • Onglyza may reduce after-meal blood sugar spikes and may help lower blood sugar between meals.
  • Onglyza may help significantly lower your A1C. A1C is the test done by your doctor every 3 months. Ask your doctor for your A1C score. It's an important step in managing your type 2 diabetes.
  • Onglyza is a once-daily pill that works for 24 hours.
  • Onglyza can be taken with or without food.
  • In clinical trials, Onglyza did not affect most people's weight.

Easy and Instant Saving for eligible patients

Get Info

Learn how Onglyza can help you achieve better blood sugar control.

What You Need To Know
Get Extra Control

IMPORTANT INFORMATION ABOUT ONGLYZA™ (saxagliptin)

Approved Uses

ONGLYZA™ (saxagliptin) is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes mellitus.

ONGLYZA has not been studied with insulin.

ONGLYZA should not be used to treat people with type 1 diabetes or to treat diabetic ketoacidosis (dangerously high levels of certain acids, known as ketones, in the blood or urine).

Important Safety Information

When ONGLYZA is used with certain other diabetes medicines to treat high blood sugar, such as a sulfonylurea, low blood sugar (hypoglycemia) may occur. Symptoms of low blood sugar include shaking, hunger, sweating, headache, rapid heartbeat, change in mood, and change in vision. Follow your healthcare provider's instructions for treating low blood sugar.

If you have allergic (hypersensitivity) reactions, such as rash, hives, and swelling of the face, lips, and throat, stop taking ONGLYZA and call your healthcare provider right away.

When ONGLYZA is used with a thiazolidinedione (TZD), such as pioglitazone or rosiglitazone, to treat high blood sugar, peripheral edema (fluid retention) may become worse. If you have symptoms of peripheral edema, such as swelling of hands, feet, or ankles, call your healthcare provider.

The most common side effects with ONGLYZA include upper respiratory tract infection, urinary tract infection, and headache.

Your healthcare provider should test your blood to measure how well your kidneys work. You may need a lower dose of ONGLYZA if your kidneys are not working well.

Tell your healthcare provider if you start or stop taking other medications, including antibiotics, antifungals or HIV/AIDS medications, as your healthcare provider may need to change your dose of ONGLYZA.

Tell your healthcare provider if you are pregnant or breast-feeding, or plan to become pregnant or breast-feed.

Please see US Full Prescribing Information, including Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.